Clene Stock Forum

$Clene (CLNN.US)$
Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants
Benzinga· 17 mins ago1min
Clene(CLNN.US)
Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-r...

$Clene (CLNN.US)$
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Tuesday, 25th February at 8:00 am
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers
APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data
Clene plans to analyze the APST ALS NfL biomarker a...

$Clene (CLNN.US)$ (((((((.         Clene Inc. has entered into an equity distribution agreement to offer and sell up to $7.39 million of common stock through Canaccord Genuity. The at-the-market offering will be used to fund clinical development of CNM-Au8, Clene's lead drug candidate for neurological disorders like ALS and MS.
The company recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS. Clene plans to provide additional biomark...

$Clene (CLNN.US)$ Reuters
1 min ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS

$Clene (CLNN.US)$ Clene Met With FDA on Nov 1 in Type C Meeting to Discuss Potential for Accelerated Approval Pathway in ALS >CLNN
Dow Jones· just

$Clene (CLNN.US)$ Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.

$Clene (CLNN.US)$ wonder it will punch above cloud...dam...

$Clene (CLNN.US)$ IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
Wed, Oct 2, 2024 at 7:21 AM EDT
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES, CA - (NewMediaWire) - October 2, 2024 - Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal functio...

$Clene (CLNN.US)$ who tf selling it off??

$Clene (CLNN.US)$
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
Clene Inc. (Nasdaq: CLNN) has submitted new CNM-Au8 biomarker and clinical efficacy data to the FDA for ALS treatment. Key findings include:
1. CNM-Au8 NfL Responders showed significant improvements in survival, functional status, and combined function and survival.
2. Long-term CNM-Au8 treatmentdemonstrated substantial survival benefits compared to matched cont...